Published on
October 14, 2022

Psychedelic Weekly Headlines | October 14

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

COMPASS Pathways ($CMPS) announced their Phase III pivotal program design for COMP360 psilocybin therapy in treatment resistant depression. The program will include two clinical trials and one long-term follow-up and will be the first ever Phase III trial of psilocybin therapy. Press Release

PharmAla Biotech ($MDMA) contracted Clerkenwell Health, a UK-based contract research organization, to provide regulatory support for both US FDA and UK MHRA applications of their novel MDMA analogue. ALA-002 was designed to provide the same efficacy as MDMA with an improved safety profile. Press Release

Optimi Health ($OPTI | $OPTHF) closed their private placement, raising $1.85M. Optimi plans to use the new growth capital to support their psychedelic product commercialization efforts, ongoing psilocybin and MDMA research, clinical trial initiatives, and in-house drug development. Press Release

IntelGenx ($IGX | $IGXT) announced that atai Life Sciences has begun the first-in-human Phase I clinical study of an oral thin film psychedelic drug candidate using IntelGenx's oral film as a potential delivery method of their Buccal VLS-01 DMT for treatment-resistant depression. Press Release

Biomind Labs ($BMND | $BMNDF) announced a Pre-Investigational New Drug meeting granted by the FDA for their new chemical entity Triptax. Triptax will be used as an active pharmaceutical ingredient or as a chemical precursor for Biomind’s novel formulations to treat depression. Press Release

Algernon Pharmaceuticals ($AGN | $AGNPF) announced that Dr. Rick Strassman, author of the book DMT: The Spirit Molecule, will be joining CEO Christopher J. Moreau for the Science Keynote Address at Wonderland Conference. The Keynote Address will review the positive preclinical science and data from Algernon's Phase I clinical study of DMT for the treatment of stroke. Press Release

Lobe Sciences ($LOBE | $LOBEF) completed the synthesis of L-130, a proprietary form of psilocin, to be used in upcoming trials with two contract research organizations. The L-130 was manufactured in compliance with U.S. cGMPs. Press Release


Vogue: Can Psilocybin Challenge Our Pharmaceutical Dependence?          

CBS: Ballot Measure Would Make Colorado Second State In The Country To Decriminalize Psychedelic          

Forbes: To Standardize Psychedelic Therapy, A New Organization Launches          

Business Insider: Exploring How Psychedelics Can Help With Alzheimer's          

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.